Cogent Biosciences (COGT) Net Cash Flow (2017 - 2026)

Cogent Biosciences' Net Cash Flow history runs 10 years deep, the most recent figure standing at -$70.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 354.34% year-over-year to -$70.8 million; the TTM figure through Mar 2026 stood at $115.6 million (up 228.76% YoY), while the FY2025 annual figure was $214.3 million, up 376.82% from the prior year.
• Net Cash Flow was -$70.8 million for Q1 2026 at Cogent Biosciences, down from $186.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $186.8 million in Q4 2025 to a low of -$185.0 million in Q3 2022.
• Historically, Net Cash Flow has averaged $1.2 million across 5 years, with a median of $1.1 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow tumbled 4823.9% in 2023, then surged 16578.12% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$682000.0 in 2022, then sank by 4823.9% to -$33.6 million in 2023, then jumped by 103.34% to $1.1 million in 2024, then soared by 16578.12% to $186.8 million in 2025, then sank by 137.9% to -$70.8 million in 2026.
• The last three Net Cash Flow figures came in at -$70.8 million (Q1 2026), $186.8 million (Q4 2025), and -$2.0 million (Q3 2025), per Business Quant data.